Juliette Montanari
Research Subjects
Juliette Montanari has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- François Chevalier
Centre de recherche sur les Ions les Matériaux et la Photonique, Université de Caen Normandie, CEA, CNRS, ENSICAEN, UMR6252 CIMAP, Team Applications in Radiobiology with Accelerated Ions, 14000 Caen, France
2 shared publications - Antoine Gilbert
ARCHADE, Association for “Advanced Resource Center for Hadrontherapy in Europe”, 14000 Caen, France
1 shared publication - Delphine Lerouge
Ctr Francois Baclesse, Dept Radiat Oncol, Caen, France
1 shared publication - Diana Savu
Department of Life and Environmental Physics, Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, 077125 Magurele, Romania
1 shared publication - Hubert Curcio
Department of Medical Oncology, Comprehensive Cancer Center François-Baclesse, 3, Avenue du Général Harris, 14076 Caen, France
1 shared publication - Jacques Balosso
Department of Radiation Oncology, Centre Francois Baclesse, 14000 Caen, France
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions
Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can be explained by the particular composition of the tumor, which develops within a dense cartilaginous matrix, producing a resistant area where the oxygen tension is very low. This microenvironment forces the cells to adapt and dedifferentiate into cancer stem cells, which are described to be more resistant to conventional treatments. One of the main avenues considered to treat this type of tumor is hadrontherapy, in particular for its ballistic properties but also its greater biological effectiveness against tumor cells. In this review, we describe the different forms of chondrosarcoma resistance and how hadrontherapy, combined with other treatments involving targeted inhibitors, could help to better treat high-grade chondrosarcoma.
Top Cited PapersOpen AccessChondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions
Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can be explained by the particular composition of the tumor, which develops within a dense cartilaginous matrix, producing a resistant area where the oxygen tension is very low. This microenvironment forces the cells to adapt and dedifferentiate into cancer stem cells, which are described to be more resistant to conventional treatments. One of the main avenues considered to treat this type of tumor is hadrontherapy, in particular for its ballistic properties but also its greater biological effectiveness against tumor cells. In this review, we describe the different forms of chondrosarcoma resistance and how hadrontherapy, combined with other treatments involving targeted inhibitors, could help to better treat high-grade chondrosarcoma.
- Open Access
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
Survival in unresectable locally advanced stage non-small cell lung cancer (NSCLC) patients remains poor despite chemoradiotherapy. Recently, adjuvant immunotherapy improved survival for these patients but we are still far from curing most of the patients with only a 57% survival remaining at 3 years. This poor survival is due to the resistance to chemoradiotherapy, local relapses, and distant relapses. Several biological mechanisms have been found to be involved in the chemoradioresistance such as cancer stem cells, cancer mutation status, or the immune system. New drugs to overcome this radioresistance in NSCLCs have been investigated such as radiosensitizer treatments or immunotherapies. Different modalities of radiotherapy have also been investigated to improve efficacity such as dose escalation or proton irradiations. In this review, we focused on biological mechanisms such as the cancer stem cells, the cancer mutations, the antitumor immune response in the first part, then we explored some strategies to overcome this radioresistance in stage III NSCLCs with new drugs or radiotherapy modalities.
Open AccessRadioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
Survival in unresectable locally advanced stage non-small cell lung cancer (NSCLC) patients remains poor despite chemoradiotherapy. Recently, adjuvant immunotherapy improved survival for these patients but we are still far from curing most of the patients with only a 57% survival remaining at 3 years. This poor survival is due to the resistance to chemoradiotherapy, local relapses, and distant relapses. Several biological mechanisms have been found to be involved in the chemoradioresistance such as cancer stem cells, cancer mutation status, or the immune system. New drugs to overcome this radioresistance in NSCLCs have been investigated such as radiosensitizer treatments or immunotherapies. Different modalities of radiotherapy have also been investigated to improve efficacity such as dose escalation or proton irradiations. In this review, we focused on biological mechanisms such as the cancer stem cells, the cancer mutations, the antitumor immune response in the first part, then we explored some strategies to overcome this radioresistance in stage III NSCLCs with new drugs or radiotherapy modalities.